drugset / Trial / NCT03238898

Botulinum Toxin for Cramps in Diabetic Neuropathy

NCT03238898

Phase 2 Completed 50 enrolled Presidio Ospedaliero Garibaldi-Centro
RandomizedParallel-groupSingle-blindTreatment

Summary

Objective: previous studies suggest that botulinum toxin A (BoNT/A) can reduce muscle hyperactivity. Research Design and Methods: a single-center, double-blind and placebo-controlled study investigating the efficacy and safety of BoNT/A intramuscular injection for treating calf or foot cramps refractory to common pharmacological drugs in patients with diabetic peripheral neuropathy. Fifty patients were subdivided in two matched groups (cases and controls) and BoNT/A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps. Responders were evaluated again with a second BoNT/A administration. The changes of pain intensity (primary outcome) and the changes in cramp frequency, the and the Cramp Severity Scale (CSS) were evaluated over the course of 20 weeks after BoNT/A administration.

Timeline

Start
2014-09-27
Primary completion
2017-05-03
Completion
2017-05-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 30 iu
Comparator Botulinum toxin type A Protein / enzyme biologic 100 iu